Evogene
EVGN
21 hedge funds and large institutions have $43.6M invested in Evogene in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0.58% more ownership
Funds ownership: 30.63% → 31.21% (+0.58%)
2% less capital invested
Capital invested by funds: $44.5M → $43.6M (-$852K)
5% less funds holding
Funds holding: 22 → 21 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$2.07M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$501K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$270K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$89.9K |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$30.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$1.64M |
| 2 |
Jane Street
New York
|
-$268K |
| 3 |
Morgan Stanley
New York
|
-$5.17K |
| 4 |
SWM
Stockman Wealth Management
Billings,
Montana
|
-$1.29K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
EVGN Hedge Fund Activity: Q2 2017 in Review
21 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q2 2017, worth a combined $43.6M — down 1.9% from $44.5M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of EVGN and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 6 added.
The largest buyer was Canada Pension Plan Investment Board, adding an estimated $2.07M. The largest seller was Goldman Sachs, cutting an estimated $1.64M.
- 21 institutional investors held Evogene (EVGN) as of Q2 2017, down from 22 in Q1 2017.
- Funds reported $43.6M of Evogene stock for Q2 2017, down 1.9% quarter-over-quarter.
- 1 fund opened new Evogene positions in Q2 2017 and 2 closed out, a net change of -1 holder.
- The largest Evogene buyer in Q2 2017 was Canada Pension Plan Investment Board, an estimated $2.07M added.
- The largest Evogene seller in Q2 2017 was Goldman Sachs, an estimated $1.64M sold.
Based on aggregated 13F filings for Q2 2017.